Phio Pharmaceuticals (PHIO) Competitors $2.09 +0.02 (+0.97%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$2.07 -0.02 (-0.96%) As of 08/22/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHIO vs. RENB, HYPD, RNXT, KLTO, EGRX, SNTI, LVTX, COEP, ACRV, and CALCShould you be buying Phio Pharmaceuticals stock or one of its competitors? The main competitors of Phio Pharmaceuticals include Renovaro (RENB), Hyperion DeFi (HYPD), RenovoRx (RNXT), Klotho Neurosciences (KLTO), Eagle Pharmaceuticals (EGRX), Senti Biosciences (SNTI), LAVA Therapeutics (LVTX), Coeptis Therapeutics (COEP), Acrivon Therapeutics (ACRV), and CalciMedica (CALC). These companies are all part of the "pharmaceutical products" industry. Phio Pharmaceuticals vs. Its Competitors Renovaro Hyperion DeFi RenovoRx Klotho Neurosciences Eagle Pharmaceuticals Senti Biosciences LAVA Therapeutics Coeptis Therapeutics Acrivon Therapeutics CalciMedica Phio Pharmaceuticals (NASDAQ:PHIO) and Renovaro (NASDAQ:RENB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership. Which has more risk & volatility, PHIO or RENB? Phio Pharmaceuticals has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, Renovaro has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Which has higher valuation and earnings, PHIO or RENB? Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Renovaro, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhio PharmaceuticalsN/AN/A-$7.15M-$3.25-0.64RenovaroN/AN/A-$88.43M-$0.77-0.31 Do institutionals and insiders hold more shares of PHIO or RENB? 57.3% of Phio Pharmaceuticals shares are held by institutional investors. Comparatively, 71.4% of Renovaro shares are held by institutional investors. 0.9% of Phio Pharmaceuticals shares are held by insiders. Comparatively, 0.5% of Renovaro shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor PHIO or RENB? In the previous week, Phio Pharmaceuticals had 2 more articles in the media than Renovaro. MarketBeat recorded 2 mentions for Phio Pharmaceuticals and 0 mentions for Renovaro. Phio Pharmaceuticals' average media sentiment score of 0.39 beat Renovaro's score of 0.00 indicating that Phio Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Phio Pharmaceuticals Neutral Renovaro Neutral Do analysts prefer PHIO or RENB? Phio Pharmaceuticals presently has a consensus price target of $14.00, indicating a potential upside of 569.86%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Phio Pharmaceuticals is more favorable than Renovaro.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Renovaro 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is PHIO or RENB more profitable? Renovaro's return on equity of -60.38% beat Phio Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Phio PharmaceuticalsN/A -88.75% -77.98% Renovaro N/A -60.38%-47.04% SummaryPhio Pharmaceuticals beats Renovaro on 8 of the 13 factors compared between the two stocks. Get Phio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHIO vs. The Competition Export to ExcelMetricPhio PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.85M$2.54B$5.75B$9.62BDividend YieldN/A1.57%4.40%4.10%P/E Ratio-0.6422.6131.2226.05Price / SalesN/A554.13435.36102.67Price / CashN/A180.4637.7358.48Price / Book1.195.939.536.61Net Income-$7.15M$31.83M$3.26B$265.65M7 Day Performance-4.13%1.89%2.11%2.02%1 Month Performance-17.72%1.33%2.79%-0.31%1 Year Performance-35.69%8.84%30.64%19.06% Phio Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHIOPhio Pharmaceuticals2.888 of 5 stars$2.09+1.0%$14.00+569.9%-31.7%$11.85MN/A-0.6410Analyst DowngradeGap UpRENBRenovaroN/A$0.24-3.4%N/A-63.7%$42.41MN/A-0.3120HYPDHyperion DeFi0.3675 of 5 stars$7.83+5.0%$2.00-74.5%-85.9%$41.80M$60K-0.1340Gap DownRNXTRenovoRx2.886 of 5 stars$1.12-2.2%$7.25+550.2%-3.1%$41.69M$40K-2.796News CoverageAnalyst UpgradeShort Interest ↓Analyst RevisionKLTOKlotho NeurosciencesN/A$0.83-8.0%N/AN/A$41.64MN/A-2.31N/AEarnings ReportGap DownEGRXEagle Pharmaceuticals1.7562 of 5 stars$3.20+0.3%N/AN/A$41.56M$257.55M0.00100SNTISenti Biosciences2.6035 of 5 stars$1.52-3.8%$8.50+459.2%-38.6%$41.33M$2.56M-0.174LVTXLAVA Therapeutics1.5341 of 5 stars$1.52-0.7%$2.69+76.6%-18.2%$40.25M$11.98M-1.4660Short Interest ↓COEPCoeptis Therapeutics0.7112 of 5 stars$11.06-0.9%N/A+228.9%$39.21MN/A-1.912News CoveragePositive NewsShort Interest ↑ACRVAcrivon Therapeutics2.5769 of 5 stars$1.23-0.8%$17.71+1,340.2%-84.3%$38.88MN/A-0.5558CALCCalciMedica3.3109 of 5 stars$2.76+0.7%$16.00+479.7%-33.5%$38.28MN/A-1.7730Gap Up Related Companies and Tools Related Companies RENB Competitors HYPD Competitors RNXT Competitors KLTO Competitors EGRX Competitors SNTI Competitors LVTX Competitors COEP Competitors ACRV Competitors CALC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHIO) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phio Pharmaceuticals Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access